The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
261
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
Time frame: Baseline, Week 26
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
Time frame: Baseline, Week 26
Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26
Response is defined as reduction of the MG-ADL total score by \>= 3 points from baseline at Week 26.
Time frame: Baseline up to Week 26
Percentage of Responders based on Reduction of the QMG Total Score at Week 26
Response is defined as reduction of the QMG total score by \>= 5 points from baseline at Week 26
Time frame: Baseline up to Week 26
Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26
Time frame: Baseline, Week 26
Change from Baseline in the QMG total score at Week 4
Time frame: Baseline, Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Orange, California, United States
Research Site
Fort Collins, Colorado, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Bradenton, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Gainesville, Georgia, United States
Research Site
Savannah, Georgia, United States
Research Site
Springfield, Illinois, United States
...and 122 more locations